

February 13, 2014

In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.

| Name | Novo A/S | |
|--|--|--|
| Relation/category of close relation | Novo A/S is closely related to the chairman of | |
| | Novozymes' board of directors, Henrik Gürtler | |
| Trading date | February 12, 2014 | |
| Market | Nasdaq OMX Copenhagen A/S | |
| Character of transaction | Sale of shares | |
| Volume of transaction buy(+)/ sell (-) | -147,800 | |
| Value of transaction (DKK) | 35,153,417.10 DKK | |

This sale has been completed according to earlier communicated intention by Novo A/S to keep its relative holding of Novozymes B shares at the level it held prior to Novozymes' cancellation of B shares on 5 April 2013 (Company announcement no. 50, August, 2011).

Contact information

| Investor Relations: | | |
|---------------------|-----------------|---------------------------|
| Thomas Bomhoff (DK) | +45 3077 1226 | <u>tsbm@novozymes.com</u> |
| Klaus Sindahl (DK) | +45 5363 0134 | ksdh@novozymes.com |
| Martin Riise (USA) | +1 919 649 2565 | mrsn@novozymes.com |

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at <u>WWW.NOVOZYMES.COM</u>.

Krogshoejvej 36 2880 Bagsvaerd Denmark Telephone: +45 4446 0000 Email: novozymesIR@novozymes.com Internet: www.novozymes.com